Hangzhou Tigermed Consulting Co., Ltd（stock symbol: 300347） is a leading Contract Research Organization (CRO) in China dedicated to provide professional full clinical trial services. Since inception in 2004, Tigermed has been committed to accelerating medical product development with costs efficiency and quality.

Headquartered in Hangzhou, Tigermed operates 9 subsidiaries, 42 offices across China and 2 overseas offices in Hong Kong and USA, with over 700 full time staffs. Tigermed has set up industrial standard SOPs and serviced more than 300 local and global clients in the conduct of over 300 clinical trials. Tigermed is recognized as “The Innovative CRO” in China，owning to our involvement of 42 innovative drugs (29 NCEs and 13 NBEs).